18 results on '"Inzucchi, Silvio E."'
Search Results
2. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
- Author
-
Wanner, Christoph, Inzucchi, Silvio E., Lachin, John M., Fitchett, David, von Eynatten, Maximilian, Mattheus, Michaela, Johansen, Odd Erik, Woerle, Hans J., Broedl, Uli C., Zinman, Bernard, and EMPA-REG OUTCOME Investigators
- Subjects
- *
DRUG side effects , *EMPAGLIFLOZIN , *KIDNEY diseases , *DISEASE progression , *TYPE 2 diabetes risk factors , *CARDIOVASCULAR diseases risk factors , *GLOMERULAR filtration rate , *TYPE 2 diabetes complications , *ALBUMINURIA , *BENZENE , *BLOOD vessels , *CARDIOVASCULAR diseases , *CLINICAL trials , *COMPARATIVE studies , *DIABETIC nephropathies , *GLYCOSIDES , *HYPOGLYCEMIC agents , *KIDNEYS , *RESEARCH methodology , *MEDICAL cooperation , *TYPE 2 diabetes , *RESEARCH , *EVALUATION research , *RANDOMIZED controlled trials , *PROPORTIONAL hazards models , *KAPLAN-Meier estimator , *THERAPEUTICS - Abstract
Background: Diabetes confers an increased risk of adverse cardiovascular and renal events. In the EMPA-REG OUTCOME trial, empagliflozin, a sodium-glucose cotransporter 2 inhibitor, reduced the risk of major adverse cardiovascular events in patients with type 2 diabetes at high risk for cardiovascular events. We wanted to determine the long-term renal effects of empagliflozin, an analysis that was a prespecified component of the secondary microvascular outcome of that trial.Methods: We randomly assigned patients with type 2 diabetes and an estimated glomerular filtration rate of at least 30 ml per minute per 1.73 m(2) of body-surface area to receive either empagliflozin (at a dose of 10 mg or 25 mg) or placebo once daily. Prespecified renal outcomes included incident or worsening nephropathy (progression to macroalbuminuria, doubling of the serum creatinine level, initiation of renal-replacement therapy, or death from renal disease) and incident albuminuria.Results: Incident or worsening nephropathy occurred in 525 of 4124 patients (12.7%) in the empagliflozin group and in 388 of 2061 (18.8%) in the placebo group (hazard ratio in the empagliflozin group, 0.61; 95% confidence interval, 0.53 to 0.70; P<0.001). Doubling of the serum creatinine level occurred in 70 of 4645 patients (1.5%) in the empagliflozin group and in 60 of 2323 (2.6%) in the placebo group, a significant relative risk reduction of 44%. Renal-replacement therapy was initiated in 13 of 4687 patients (0.3%) in the empagliflozin group and in 14 of 2333 patients (0.6%) in the placebo group, representing a 55% lower relative risk in the empagliflozin group. There was no significant between-group difference in the rate of incident albuminuria. The adverse-event profile of empagliflozin in patients with impaired kidney function at baseline was similar to that reported in the overall trial population.Conclusions: In patients with type 2 diabetes at high cardiovascular risk, empagliflozin was associated with slower progression of kidney disease and lower rates of clinically relevant renal events than was placebo when added to standard care. (Funded by the Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance; EMPA-REG OUTCOME ClinicalTrials.gov number, NCT01131676.). [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
3. Clinical practice. Diagnosis of diabetes.
- Author
-
Inzucchi, Silvio E
- Published
- 2012
4. Diagnosis of Diabetes.
- Author
-
Inzucchi, Silvio E.
- Subjects
- *
HYPERTENSION , *DISEASES in men , *ATENOLOL , *TYPE 2 diabetes , *BODY mass index , *BLOOD pressure , *DIAGNOSIS of diabetes - Abstract
The article presents a case study of a 42-year-old man with hypertension. The patient received atenolol and chlorthadilone and his parents have type 2 diabetes. His body-mass index and blood pressure were given and the ways for screening this patient for diabetes were assessed. Information about the implications of making diagnosis for diabetes in a patient is mentioned, as well as the various screening tests for diabetes.
- Published
- 2012
- Full Text
- View/download PDF
5. Glucose Control in the ICU — How Tight Is Too Tight?
- Author
-
Inzucchi, Silvio E. and Siegel, Mark D.
- Subjects
- *
BLOOD sugar , *HYPERGLYCEMIA prevention , *CRITICALLY ill , *MEDICAL care ,RESEARCH evaluation - Abstract
The authors express their opinion regarding the Normoglycemia in Intensive Care Evaluation-Survival Using Glucose Algorithm Regulation (NICE-SUGAR) trial reported in the issue. The trial found increased mortality in a group receiving intensive blood glucose control. The authors believe that further exploration is needed to determine the precise causes of death in the patients. They caution against overreaction to the NICE-SUGAR findings.
- Published
- 2009
- Full Text
- View/download PDF
6. New Treatments for Diabetes.
- Author
-
Bloomgarden, Zachary T. and Inzucchi, Silvio E.
- Subjects
- *
LETTERS to the editor , *TREATMENT of diabetes - Abstract
This article presents a letter to the editor in response to "Finding new treatments for diabetes: how many, how fast...how good?" by D.M. Nathan in the February 1, 2007 issue.
- Published
- 2007
- Full Text
- View/download PDF
7. Management of Hyperglycemia in Hospitalized, Non-Critically Ill Adults.
- Author
-
Chang, Leslie L., Umpierrez, Guillermo E., and Inzucchi, Silvio E.
- Subjects
- *
HYPERGLYCEMIA , *HOSPITAL care - Abstract
The article presents a case study of a 72-year-old woman with a body-mass index, had a 5-year history of type 2 non-insulin-dependent diabetes mellitus without complications presents to the emergency department with fevers, cough, and decreased oral intake. It discusses the treatment provided to the patient.
- Published
- 2022
- Full Text
- View/download PDF
8. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
- Author
-
Wanner, Christoph, Inzucchi, Silvio E., and Zinman, Bernard
- Subjects
- *
EMPAGLIFLOZIN , *KIDNEY glomerulus , *TYPE 2 diabetes - Abstract
A response from the authors of the United Kingdom Prospective Diabetes Study concerning the direct effects of empagliflozin on glomerular cells is presented.
- Published
- 2016
- Full Text
- View/download PDF
9. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
- Author
-
McMurray, John J. V., Solomon, Scott D., Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Martinez, Felipe A., Ponikowski, Piotr, Sabatine, Marc S., Anand, Inder S., Bělohlávek, Jan, Böhm, Michael, Chiang, Chern-En, Chopra, Vijay K., de Boer, Rudolf A., Desai, Akshay S., Diez, Mirta, Drozdz, Jaroslaw, Dukát, Andrej, Ge, Junbo, and Howlett, Jonathan G.
- Abstract
BACKGROUND In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 diabetes. METHODS In this phase 3, placebo-controlled trial, we randomly assigned 4744 patients with New York Heart Association class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either dapagliflozin (at a dose of 10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of worsening heart failure (hospitalization or an urgent visit resulting in intravenous therapy for heart failure) or cardiovascular death. RESULTS Over a median of 18.2 months, the primary outcome occurred in 386 of 2373 patients (16.3%) in the dapagliflozin group and in 502 of 2371 patients (21.2%) in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.65 to 0.85; P<0.001). A first worsening heart failure event occurred in 237 patients (10.0%) in the dapagliflozin group and in 326 patients (13.7%) in the placebo group (hazard ratio, 0.70; 95% CI, 0.59 to 0.83). Death from cardiovascular causes occurred in 227 patients (9.6%) in the dapagliflozin group and in 273 patients (11.5%) in the placebo group (hazard ratio, 0.82; 95% CI, 0.69 to 0.98); 276 patients (11.6%) and 329 patients (13.9%), respectively, died from any cause (hazard ratio, 0.83; 95% CI, 0.71 to 0.97). Findings in patients with diabetes were similar to those in patients without diabetes. The frequency of adverse events related to volume depletion, renal dysfunction, and hypoglycemia did not differ between treatment groups. CONCLUSIONS Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than among those who received placebo, regardless of the presence or absence of diabetes. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
10. Management of Hyperglycemia in the Hospital Setting.
- Author
-
Inzucchi, Silvio E.
- Subjects
- *
HYPERGLYCEMIA , *INSULIN therapy , *BLOOD sugar , *GLUCOSE tolerance tests , *GLYCOSYLATED hemoglobin , *PEOPLE with diabetes , *MEDICAL care research - Abstract
This article presents a hypothetical situation in which an asthmatic woman with pneumonia and hyperglycemia is admitted to a hospital. The situation requires that a decision is made regarding treatment for the woman's hyperglycemia, as she is not a diagnosed diabetic. The author presents the argument that hyperglycemia was once simply considered an accepted by-product of severe illness. Statistics related to the relationship between hyperglycemia and infection in hospitalized and post-operative patients are provided. Statistics and analysis related to insulin treatment for diabetics is included. A flow chart detailing how to treat a patient based on glucose control and other factors is also provided.
- Published
- 2006
- Full Text
- View/download PDF
11. Nonalcoholic Fatty Liver Disease.
- Author
-
Inzucchi, Silvio E., Petersen, Kitt F., and Shulman, Gerald I.
- Subjects
- *
LETTERS to the editor , *FATTY liver - Abstract
A letter to the editor is presented in response to the article "Nonalcoholic Fatty Liver Disease," by P. Angulo in the April 18, 2006 issue.
- Published
- 2002
- Full Text
- View/download PDF
12. Mediastinal Goiter.
- Author
-
Inzucchi, Silvio E. and Brunet, Cristina M.
- Subjects
- *
GOITER , *DIAGNOSTIC imaging , *RADIOIODINATION , *TOMOGRAPHY , *RADIOGRAPHY - Abstract
The article presents images of a chest radiograph, computed tomograph of the thorax, and radioiodine scan of a 51-year-old woman with a mediastinal mass, along with information on her condition.
- Published
- 1998
- Full Text
- View/download PDF
13. Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus.
- Author
-
Inzucchi, Silvio E., Maggs, David G., Spollett, Geralyn R., Page, Stephanie L., Rife, Frances S., Walton, Veronika, and Shulman, Gerald I.
- Subjects
- *
TREATMENT of diabetes - Abstract
Background: Combination therapy is logical for patients with non-insulin-dependent (type II) diabetes mellitus, because they often have poor responses to single-drug therapy. We studied the efficacy and physiologic effects of metformin and troglitazone alone and in combination in patients with type II diabetes. Methods: We randomly assigned 29 patients to receive either metformin or troglitazone for three months, after which they were given both drugs for another three months. Plasma glucose concentrations during fasting and postprandially and glycosylated hemoglobin values were measured periodically during both treatments. Endogenous glucose production and peripheral glucose disposal were measured at base line and after three and six months. Results: During metformin therapy, fasting and postprandial plasma glucose concentrations decreased by 20 percent (58 mg per deciliter [3.2 mmol per liter], P<0.001) and 25 percent (87 mg per deciliter [4.8 mmol per liter], P<0.001), respectively. The corresponding decreases during troglitazone therapy were 20 percent (54 mg per deciliter [2.9 mmol per liter], P = 0.01) and 25 percent (83 mg per deciliter [4.6 mmol per liter], P<0.001). Endogenous glucose production decreased during metformin therapy by a mean of 19 percent (P = 0.001), whereas it was unchanged by troglitazone therapy (P = 0.04 for the comparison between groups). The mean rate of glucose disposal increased by 54 percent during troglitazone therapy (P = 0.006) and 13 percent during metformin therapy (P = 0.03 for the comparison within the group and between groups). In combination, metformin and troglitazone further lowered fasting and postprandial plasma glucose concentrations by 18 percent (41 mg per deciliter [2.3 mmol per liter], P = 0.001) and 21 percent (54 mg per deciliter [3.0 mmol per liter], P<0.001), respectively, and the mean glycosylated hemoglobin value decreased 1.2 percentage points. Conclusions: Metformin and troglitazone have equal and additive beneficial effects on glycemic control in patients with type II diabetes. Metformin acts primarily by decreasing endogenous glucose production, and troglitazone by increasing the rate of peripheral glucose disposal. (N Engl J Med 1998;338:867-72.) [ABSTRACT FROM AUTHOR]
- Published
- 1998
- Full Text
- View/download PDF
14. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
- Author
-
Bhatt, Deepak L., Szarek, Michael, Pitt, Bertram, Cannon, Christopher P., Leiter, Lawrence A., McGuire, Darren K., Lewis, Julia B., Riddle, Matthew C., Inzucchi, Silvio E., Kosiborod, Mikhail N., Cherney, David Z. I., Dwyer, Jamie P., Scirica, Benjamin M., Bailey, Clifford J., Diaz, Rafael, Ray, Kausik K., Udell, Jacob A., Lopes, Renato D., Lapuerta, Pablo, and Steg, P. Gabriel
- Subjects
- *
CHRONIC kidney failure , *SODIUM-glucose cotransporter 2 inhibitors , *PEOPLE with diabetes , *TYPE 2 diabetes , *COMPOSITE numbers - Abstract
BACKGROUND The efficacy and safety of sodium-glucose cotransporter 2 inhibitors such as sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic kidney disease with or without albuminuria have not been well studied. METHODS We conducted a multicenter, double-blind trial in which patients with type 2 diabetes mellitus (glycated hemoglobin level, >7%>), chronic kidney disease (estimated glomerular filtration rate, 25 to 60 ml per minute per 1.73 m2 of body-surface area), and risks for cardiovascular disease were randomly assigned in a 1:1 ratio to receive sotagliflozin or placebo. The primary end point was changed during the trial to the composite of the total number of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure. The trial ended early owing to loss of funding. RESULTS Of 19,188 patients screened, 10,584 were enrolled, with 5292 assigned to the sotagliflozin group and 5292 assigned to the placebo group, and followed for a median of 16 months. The rate of primary end-point events was 5.6 events per 100 patient-years in the sotagliflozin group and 7.5 events per 100 patient-years in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.63 to 0.88; P<0.001). The rate of deaths from cardiovascular causes per 100 patient-years was 2.2 with sotagliflozin and 2.4 with placebo (hazard ratio, 0.90; 95% CI, 0.73 to 1.12; P=0.35). For the original coprimary end point of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, the hazard ratio was 0.84 (95% CI, 0.72 to 0.99); for the original coprimary end point of the first occurrence of death from cardiovascular causes or hospitalization for heart failure, the hazard ratio was 0.77 (95% CI, 0.66 to 0.91). Diarrhea, genital mycotic infections, volume depletion, and diabetic ketoacidosis were more common with sotagliflozin than with placebo. CONCLUSIONS In patients with diabetes and chronic kidney disease, with or without albuminuria, sotagliflozin resulted in a lower risk of the composite of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo but was associated with adverse events. (Funded by Sanofi and Lexicon Pharmaceuticals; SCORED ClinicalTrials.gov number, NCT03315143.). [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. THE AUTHORS REPLY.
- Author
-
Zinman, Bernard, Lachin, John M., and Inzucchi, Silvio E.
- Abstract
A response from the author of the article "Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes" in the November 15, 2013 issue is presented.
- Published
- 2016
- Full Text
- View/download PDF
16. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
- Author
-
Zinman, Bernard, Wanner, Christoph, Lachin, John M., Fitchett, David, Bluhmki, Erich, Hantel, Stefan, Mattheus, Michaela, Devins, Theresa, Johansen, Odd Erik, Woerle, Hans J., Broedl, Uli C., Inzucchi, Silvio E., and EMPA-REG OUTCOME Investigators
- Subjects
- *
CARDIOVASCULAR disease prevention , *BENZENE , *CARDIOVASCULAR diseases , *CLINICAL trials , *COMPARATIVE studies , *CAUSES of death , *GLYCOSIDES , *HOSPITAL care , *HYPOGLYCEMIC agents , *RESEARCH methodology , *MEDICAL cooperation , *TYPE 2 diabetes , *RESEARCH , *EVALUATION research , *RANDOMIZED controlled trials , *KAPLAN-Meier estimator , *THERAPEUTICS ,CARDIOVASCULAR disease related mortality - Abstract
Background: The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.Methods: We randomly assigned patients to receive 10 mg or 25 mg of empagliflozin or placebo once daily. The primary composite outcome was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, as analyzed in the pooled empagliflozin group versus the placebo group. The key secondary composite outcome was the primary outcome plus hospitalization for unstable angina.Results: A total of 7020 patients were treated (median observation time, 3.1 years). The primary outcome occurred in 490 of 4687 patients (10.5%) in the pooled empagliflozin group and in 282 of 2333 patients (12.1%) in the placebo group (hazard ratio in the empagliflozin group, 0.86; 95.02% confidence interval, 0.74 to 0.99; P=0.04 for superiority). There were no significant between-group differences in the rates of myocardial infarction or stroke, but in the empagliflozin group there were significantly lower rates of death from cardiovascular causes (3.7%, vs. 5.9% in the placebo group; 38% relative risk reduction), hospitalization for heart failure (2.7% and 4.1%, respectively; 35% relative risk reduction), and death from any cause (5.7% and 8.3%, respectively; 32% relative risk reduction). There was no significant between-group difference in the key secondary outcome (P=0.08 for superiority). Among patients receiving empagliflozin, there was an increased rate of genital infection but no increase in other adverse events.Conclusions: Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care. (Funded by Boehringer Ingelheim and Eli Lilly; EMPA-REG OUTCOME ClinicalTrials.gov number, NCT01131676.). [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
17. New treatments for diabetes.
- Author
-
Bloomgarden ZT, Inzucchi SE, Irony I, Parks MH, Meyer RJ, Mintz ML, Raz I, Eldor R, Nathan DM, Bloomgarden, Zachary T, and Inzucchi, Silvio E
- Published
- 2007
18. Diagnosis of Diabetes.
- Author
-
Yu Chen, Rodríguez-Gutiérrez, René, González-Saldivar, Gloria, González-González, José G., and Inzucchi, Silvio E.
- Subjects
- *
DIABETES , *ENDOCRINE diseases - Abstract
Two letters to the editor in response to an article about the combined screening for diabetes which appeared in the August 9, 2012 issue as well as the reply of the author are presented.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.